Renaissance Capital logo

NTLA News

US IPO Weekly Recap: Biotechs get pushback, but gene editing still soars

NTLA

Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying. ...read more

Intellia Therapeutics prices upsized IPO at $18, the high end of the range

NTLA

Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, raised $108 million by offering 6 million shares at $18, the high end of the range of $16 to $18. Intellia Therapeutics plans to list on the Nasdaq under the symbol NTLA. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal....read more

Week ahead: Biotechs Strike Back with Four IPOs

NTLA

After seven IPOs in a row outside the healthcare sector, four biotechs will attempt to price their IPOs in the week ahead, all with insider support. Looking more broadly, the next two weeks could see an increased number of launches if companies in the pipeline wish to complete their deals before the Memorial Day...read more

Gene editing biotech Intellia Therapeutics sets terms for $85 million IPO

NTLA

Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, announced terms for its IPO on Wednesday. The Cambridge , MA-based company plans to raise $85 million by offering 5 million shares at a price range of $16 to $18. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed...read more